Valuation Podcast 5: Life Science Panel Discussion
This industry is undergoing a major transformative change where life science companies are moving away from traditional ways of doing business and embracing next-generation digital technologies, such as robotic process automation, AI, machine learning, and advanced analytics and cloud-based platforms. The NCREIF Valuation Committee thought it would be interesting to hear how requirements are changing for those life science companies in hyper-expansion mode, as strong demand due to the pandemic is pressuring life science companies to produce better outcomes backed by real-world data.